2,323 research outputs found
Seasonal body mass changes in Eurasian Golden Plovers Pluvialis apricaria staging in the Netherlands: decline in late autumn mass peak correlates with increase in raptor numbers
No full textEurasian Golden Plovers Pluvialis apricaria staging in the Netherlands during the non-breeding season show strikingly constant seasonal changes in body mass with a first mass peak in late November and December and a second peak in late April and May. Despite huge sample sizes, variations in this pattern over successive years in the 1990s and among age classes were minuscule. However, in contrast to the body mass levels at other times of the year, there was a marked decline in the winter peak mass of Golden Plovers from the 1970s/early 1980s to 1989–2000. The decrease, by an average of 29 g, was about half the extra mass previously stored in autumn. This additional mass is known to consist of fat and may be interpreted as an energy store − insurance − for sudden cold spells when a negative energy balance forces the birds to move south and stay in front of the frostline. As the rate of the mass increase in September–October showed no change from the 1980s to the 1990s, changes in food availability are unlikely to explain the long-term mass decline. Also, there were no differences in two factors known to influence energy expenditure and feeding rate, air temperature and rainfall. The one striking environmental change relevant to plovers was the steep increase in the occurrence of raptors in the northern Netherlands in the 1980s, notably Peregrine Falcons Falco peregrinus and Goshawks Accipter gentilis. We argue that the halving of the winter mass peak over a decade is consistent with the hypothesis that under increased risk of predation, birds lower their body mass in order to reduce individual vulnerability, a reduction that may be traded off against an increased risk of starvation.
Blood parameter changes during stopover in a long-distance migratory shorebird, the bar-tailed godwit Limosa lapponica taymyrensis
No full textBar-tailed godwits migrate from West African wintering sites to breeding areas in northern Russia with only one stopover. We compared hematocrit (Hct), blood hemoglobin concentration (Hb), and mean cell hemoglobin concentration (MCHb; a measure of the relative proportion of Hb in the cellular blood fraction) between arriving godwits lured to land 60 km short of the stopover site and godwits during subsequent refueling. The Hct and Hb of arriving godwits was low when compared to that of refueling birds. On the stopover site, Hct and Hb correlated positively with size-corrected body mass. In addition, Hb and MCHb reached peak levels in the last days of stopover. We explored the possibility of regenerative anemia in arriving godwits by comparing the fraction of reticulocytes (young red blood cells) between arriving and refueling birds. No differences were found. Therefore, we suggest that the increase in Hct, Hb, and MCHb during refueling is not in response to a severe anemic state at arrival. Rather, we suggest that the increase in blood parameters may anticipate the increased aerobic requirements of impending migratory flight and possibly satisfy heightened oxygen demands of the larger body mass of fattened birds. The Hct increase on the stopover site may also serve to buffer the red blood cell population against possible red blood cell breakdown during long-distance flight.
Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
No full text<p>Background: Venous thromboembolic events (VTE), including deep venous thrombosis and pulmonary embolism, are common in older age. It has been suggested that statins might reduce the risk of VTE however positive results from studies of middle aged subjects may not be generalisable to elderly people. We aimed to determine the effect of pravastatin on incident VTE in older people; we also studied the impact of clinical and plasma risk variables.</p>
<p>Methods: This study was an analysis of incident VTE using data from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), a randomized, double-blind, placebo-controlled trial of pravastatin in men and women aged 70-82. Mean follow-up was 3.2 years. Risk for VTE was examined in non-warfarin treated pravastatin (n = 2834) and placebo (n = 2865) patients using a Cox's proportional hazard model, and the impact of other risk factors assessed in a multivariate forward stepwise regression analysis. Baseline clinical characteristics, blood biochemistry and hematology variables, plasma levels of lipids and lipoproteins, and plasma markers of inflammation and adiposity were compared. Plasma markers of thrombosis and hemostasis were assessed in a nested case (n = 48) control (n = 93) study where the cohort was those participants, not on warfarin, for whom data were available.</p>
<p>Results: There were 28 definite cases (1.0%) of incident VTE in the pravastatin group recipients and 20 cases (0.70%) in placebo recipients. Pravastatin did not reduce VTE in PROSPER compared to placebo [unadjusted hazard ratio (95% confidence interval) 1.42 (0.80, 2.52) p = 0.23]. Higher body mass index (BMI) [1.09 (1.02, 1.15) p = 0.0075], country [Scotland vs Netherlands 4.26 (1.00, 18.21) p = 0.050 and Ireland vs Netherlands 6.16 (1.46, 26.00) p = 0.013], lower systolic blood pressure [1.35 (1.03, 1.75) p = 0.027] and lower baseline Mini Mental State Examination (MMSE) score [1.19 (1.01, 1.41) p = 0.034] were associated with an increased risk of VTE, however only BMI, country and systolic blood pressure remained significant on multivariate analysis. In a nested case control study of definite VTE, plasma Factor VIII levels were associated with VTE [1.52 (1.01, 2.28), p = 0.044]. However no other measure of thrombosis and haemostasis was associated with increased risk of VTE.</p>
<p>Conclusions: Pravastatin does not prevent VTE in elderly people at risk of vascular disease. Blood markers of haemostasis and inflammation are not strongly predictive of VTE in older age however BMI, country and lower systolic blood pressure are independently associated with VTE risk.</p>
Radio-telemetry observations of the first 650 km of the migration of Bar-tailed Godwits Limosa lapponica from the Wadden Sea to the Russian Arctic
No full textIn 1999 and 2000, 45 Bar-tailed Godwits Limosa lapponica were supplied with radio-transmitters during spring staging on the island Texel in the western Wadden Sea. With the use of Automatic Radio Tracking Stations (ARTS) on Texel and in south Sweden, and hand-held receivers on Texel, it was possible to follow the later part of the stopover period on Texel for 34 birds (76%) and the passage over south Sweden for 26 birds (58%). Thus, the method of automatic tracking of overflying migrating shorebirds works successfully where the migration corridor is narrow and predictable, as in the case with late spring shorebird migration from the Wadden Sea towards arctic Russia. The timing of departure from Texel and passage over south Sweden of radio-marked birds, with median dates of 30 May and 2 June respectively, were in agreement with published data on the spring migration of Siberian-breeding Bar-tailed Godwits L. l. taymyrensis. The individual variation in migration dates was larger than expected, with birds passing south Sweden between 25 May and 10 June, indicating that the time-window for departure might be broader than previously thought. There was no clear difference between males and females in timing of migration. The time difference between departure from Texel and passage over south Sweden (average 3.3 days) indicates that most Bar-tailed Godwits do not embark on the long flight towards Siberia directly from the western Wadden Sea, but are more likely to stop in the more easterly portion of the Wadden Sea before the final take-off. This pattern is similar to what has been found in other shorebirds and geese (e.g. Red Knots Calidris canutus and Dark-bellied Brent Geese Branta bernicla) migrating along the same route.
Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative
No full textCirculating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk
No full text<p><b>Objective:</b> The goal of this study was to examine the association of the antiinflammatory interleukin-10 (IL-10) with risk of cardiovascular disease (CVD).</p>
<p><b>Methods and Results:</b> In the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) cohort, we related baseline concentrations of circulating IL-10 to risk of CVD events in a nested case (n=819)-control (n=1618) study of 3.2 years of follow-up. Circulating IL-10 showed few strong associations with classical risk factors but was positively correlated with IL-6 and C-reactive protein. IL-10 was positively associated with risk of CVD events (odds ratio [OR] 1.17, 95% CI 1.05 to 1.31 per unit increase in log IL-10) after adjusting for classical risk factors and C-reactive protein. Furthermore, IL-10 was associated more strongly with CVD risk among those with no previous history of CVD (OR 1.42, 95% CI 1.18 to 1.70), compared with those with previous CVD (OR 1.04, 95% CI 0.90 to 1.19; P=0.018). Overall, IL-10 showed a modest ability to add discrimination to classical risk factors (C-statistic +0.005, P=0.002).</p>
<p><b>Conclusion:</b> Baseline circulating levels of the antiinflammatory IL-10 are positively associated with risk of CVD among the elderly without prior CVD events, although the association is less evident in those with a history of CVD. Additional epidemiological and mechanistic studies investigating the role of IL-10 in CVD are warranted.</p>
The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project
No full textAims: To evaluate the effect of the ESC/EAS 2019 dyslipidaemia guidelines on patient management of lipid-lowering therapy in patients with acute coronary syndrome (ACS), through a survey designed to compare post-ACS patient management in 2022 with that in 2018. Methods: Online questionnaires focused on lipid profile and medications were used to gather data from 2650 ACS patients in 6 European countries, treated between March–June 2022 (ACS EuroPath IV survey). These data were compared with data collected from 2650 patients who participated in the ACS EuroPath I survey (conducted in 2018). Results: Lipid testing was performed in 90% of patients and was done sooner after admission in 2022 versus 2018 (mean 1.4 vs 1.7 days). Increased testing for non-HDL-C, lipoprotein(a), and ApoB was observed over time. At discharge, most patients (≥90%) were receiving lipid-lowering therapy. Prescribing patterns differed, with a higher proportion of patients receiving statin plus ezetimibe combination therapy in 2022 versus 2018 (34% vs 13%). LDL-C levels were lower in 2022 versus 2018 at admission and at 1st, 2nd and 3rd post-discharge follow-up points. More patients achieved low-density lipoprotein cholesterol (LDL-C) goals in 2022 versus 2018 at the first follow-up (average 14 vs 16 weeks since discharge; <70 mg/dL [1.8 mmol/L]: 34% vs 20%; <55 mg/dL [1.4 mmol/L]: 18% vs 10%) and at subsequent follow-up points. Conclusion: LDL-C goal achievement has improved since the release of the 2019 guidelines, but lipid management in post-ACS patients remains suboptimal
Networks for improving care in patients with acute coronary syndrome: A framework
No full textIn recent years, it has become evident that the level of guideline adherence in patients presenting with acute coronary syndrome (ACS) is highly correlated with patient outcomes. Unfortunately, guideline adherence is low in some geographic areas and especially in those patients at high-risk. Regional networks including ambulance systems and hospitals with catheterization laboratories are able to increase guideline adherence and patient outcomes by streamlining the critical pre- and intra-hospital processes as well as improving timely access to invasive procedures and recommended medication. Successful organization of an ACS network requires engagement of multiple stakeholders to create effective solutions for the specific local setting. There is no 'one-size-fits all' strategy to set-up and successfully run an ACS network. We present a framework for how to set up and organize an effective ACS network, delivering guideline-based care to improve patient outcomes. Copyright © 2014 Informa UK, Ltd
- …
